FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2313997133> ?p ?o ?g. }

• W2313997133 endingPage "867" @default.
• W2313997133 startingPage "867" @default.
• W2313997133 abstract "The presence of neutropenia after kidney transplantation represents a frequent adverse event (AE) that is usually treated with lowering of mycophenolic acid (MPA) dose. This leads to an increased incidence of acute rejection episodes and potential loss of renal allograft. This study evaluated the efficacy and safety of everolimus when used instead of MPA in patients who developed neutropenia (absolute neutrophil count < 2000/μL). We studied 17 patients, 12 men and 5 women, aged 40 ± 12 years old, who developed neutropenia after kidney transplantation. Five of them were patients with high immunological risk (high titer of cytotoxic antibodies, second or third transplant). All patients treated with MPA (1912 ± 196mg/day), calcineurin inhibitor (cyclosporine n=1, tacrolimus n=16) and methylprednisolone. Neutropenia occurred in 15 patients during the first 3 months after transplantation and in 2 patients between the 3rd and 6th month post-transplantation (59 ± 38 days). The 15 patients who developed neutropenia during the first 3 months after transplantation were still on valgancyclovir as prophylaxis against cytomegalovirus (CMV) infection. A total of 118 episodes of neutropenia were recorded, originally treated by reduction of MPA dose and administration of granulocyte colony-stimulating factor (G-CSF). Three patients experienced acute rejection (Banff 1A) 5 to 10 days after the reduction of MPA dose (0-1000mg/day) which was successfully treated with IV pulse of methylprednisolone. Five patients developed CMV infection, 108 ± 65 days after the onset of neutropenia and 5.5±1.5 months after transplantation. The replacement of MPA (765 ± 390mg/day) by everolimus was performed 1 to 23 months after transplantation and 5 days up to 48 months from the onset of neutropenia. After the induction of everolimus, 50 episodes of neutropenia were observed in 6 patients. In one of them discontinuation of everolimus was necessary 1.5 month later and in the rest 5 (who developed CMV infection and treated by valgancyclovir), neutropenia of less severity was observed up to the end of treatment for CMV infection. In the remaining 11 patients, no episode of neutropenia was observed. No episode of acute rejection occurred and the renal function remained stable 6 months after initiation of everolimus and during the whole follow up period of 47±30months [eGFRMDRD6: 45±14ml/min/1.73m2 → (6months):51±16ml/min/1.73m2 → (47±30months): 47±22ml/min/1.73m2]. Conclusion: The replacement of MPA by everolimus because of neutropenia in renal transplant recipients on triple immunosuppressive regimen appears to be safe and effective alternative treatment. Although neutropenia also occurred after administration of everolimus, it was less serious and possibly due to a different mechanism of action. Further research with more prospective randomized studies is necessary in order to confirm these findings." @default.
• W2313997133 created "2016-06-24" @default.
• W2313997133 creator A5010026228 @default.
• W2313997133 creator A5014145525 @default.
• W2313997133 creator A5036521084 @default.
• W2313997133 creator A5076658591 @default.
• W2313997133 creator A5077801965 @default.
• W2313997133 creator A5081084593 @default.
• W2313997133 creator A5086154946 @default.
• W2313997133 date "2012-11-01" @default.
• W2313997133 modified "2023-09-26" @default.
• W2313997133 title "Replacement of Mycophenolic Acid by Everolimus in Patients Who Become Neutropenic after Renal Transplantation" @default.
• W2313997133 doi "https://doi.org/10.1097/00007890-201211271-01706" @default.
• W2313997133 hasPublicationYear "2012" @default.
• W2313997133 type Work @default.
• W2313997133 sameAs 2313997133 @default.
• W2313997133 citedByCount "0" @default.
• W2313997133 crossrefType "journal-article" @default.
• W2313997133 hasAuthorship W2313997133A5010026228 @default.
• W2313997133 hasAuthorship W2313997133A5014145525 @default.
• W2313997133 hasAuthorship W2313997133A5036521084 @default.
• W2313997133 hasAuthorship W2313997133A5076658591 @default.
• W2313997133 hasAuthorship W2313997133A5077801965 @default.
• W2313997133 hasAuthorship W2313997133A5081084593 @default.
• W2313997133 hasAuthorship W2313997133A5086154946 @default.
• W2313997133 hasBestOaLocation W23139971331 @default.
• W2313997133 hasConcept C126322002 @default.
• W2313997133 hasConcept C128057223 @default.
• W2313997133 hasConcept C141071460 @default.
• W2313997133 hasConcept C2776694085 @default.
• W2313997133 hasConcept C2777063308 @default.
• W2313997133 hasConcept C2777767877 @default.
• W2313997133 hasConcept C2778033501 @default.
• W2313997133 hasConcept C2779699572 @default.
• W2313997133 hasConcept C2780252810 @default.
• W2313997133 hasConcept C2780303639 @default.
• W2313997133 hasConcept C2780372218 @default.
• W2313997133 hasConcept C2781307858 @default.
• W2313997133 hasConcept C2909675724 @default.
• W2313997133 hasConcept C2911091166 @default.
• W2313997133 hasConcept C71924100 @default.
• W2313997133 hasConcept C74133956 @default.
• W2313997133 hasConcept C90924648 @default.
• W2313997133 hasConceptScore W2313997133C126322002 @default.
• W2313997133 hasConceptScore W2313997133C128057223 @default.
• W2313997133 hasConceptScore W2313997133C141071460 @default.
• W2313997133 hasConceptScore W2313997133C2776694085 @default.
• W2313997133 hasConceptScore W2313997133C2777063308 @default.
• W2313997133 hasConceptScore W2313997133C2777767877 @default.
• W2313997133 hasConceptScore W2313997133C2778033501 @default.
• W2313997133 hasConceptScore W2313997133C2779699572 @default.
• W2313997133 hasConceptScore W2313997133C2780252810 @default.
• W2313997133 hasConceptScore W2313997133C2780303639 @default.
• W2313997133 hasConceptScore W2313997133C2780372218 @default.
• W2313997133 hasConceptScore W2313997133C2781307858 @default.
• W2313997133 hasConceptScore W2313997133C2909675724 @default.
• W2313997133 hasConceptScore W2313997133C2911091166 @default.
• W2313997133 hasConceptScore W2313997133C71924100 @default.
• W2313997133 hasConceptScore W2313997133C74133956 @default.
• W2313997133 hasConceptScore W2313997133C90924648 @default.
• W2313997133 hasIssue "10S" @default.
• W2313997133 hasLocation W23139971331 @default.
• W2313997133 hasOpenAccess W2313997133 @default.
• W2313997133 hasPrimaryLocation W23139971331 @default.
• W2313997133 hasRelatedWork W1945893485 @default.
• W2313997133 hasRelatedWork W1966330977 @default.
• W2313997133 hasRelatedWork W2033382768 @default.
• W2313997133 hasRelatedWork W2056636557 @default.
• W2313997133 hasRelatedWork W2057366582 @default.
• W2313997133 hasRelatedWork W2518924070 @default.
• W2313997133 hasRelatedWork W2943755422 @default.
• W2313997133 hasRelatedWork W3164074759 @default.
• W2313997133 hasRelatedWork W4240284178 @default.
• W2313997133 hasRelatedWork W4296385730 @default.
• W2313997133 hasVolume "94" @default.
• W2313997133 isParatext "false" @default.
• W2313997133 isRetracted "false" @default.
• W2313997133 magId "2313997133" @default.
• W2313997133 workType "article" @default.